Article Text

Download PDFPDF

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
  1. Kyriakos P Papadopoulos1,
  2. Frank Tsai2,
  3. Omid Hamid3,
  4. Feng Xiao4,
  5. Keith E Steele4,
  6. Marlon C Rebelatto4,
  7. Paul B Robbins4,
  8. Joyson J Karakunnel4,
  9. Dominic W Lai4 and
  10. Amit Mahipal5
  1. Aff1 grid.477989.c0000000404347503South Texas Accelerated Research Therapeutics (START) San Antonio TX USA
  2. Aff2 grid.492843.0Pinnacle Oncology Hematology Scottsdale AZ USA
  3. Aff3 grid.488730.0The Angeles Clinic and Research Institute Los Angeles CA USA
  4. Aff4 grid.418152.bMedImmune Gaithersburg MD USA
  5. Aff5 grid.170693.a000000012353285XMoffitt Cancer Center Tampa FL USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


The immune system is able to control the growth of many types of cancers. Most tumors show infiltration by tumor infiltrating lymphocytes, but tumors modulate the local microenvironment by expressing immune-inhibitory molecules. Blockade of immune checkpoints such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and programmed cell death ligand-1 (PD-L1) has shown clinical activity in immune-responsive tumors as well as those historically deemed unresponsive to treatment. Durvalumab (MEDI4736) is a selective, high affinity human IgG1 monoclonal antibody (mAb) that blocks PD-L1 binding to PD-1 (IC50 0.1 nM) and CD80 (IC50 0.04 nM). Tremelimumab is a selective human IgG2 mAb inhibitor of CTLA-4 which promotes T-cell activity through CTLA-4 inhibition. Both durvalumab and tremelimumab have demonstrated acceptable safety profiles and promising clinical activity as single agents in multiple tumor types. Recent data suggest that combined checkpoint inhibition may generate superior antitumor activity versus monotherapy, resulting in higher, deeper, and more durable response rates, which suggests that dual inhibition may overcome barriers to immune response in historically non-immune responsive tumors. We describe an ongoing study assessing the safety and antitumor activity of durvalumab in combination with tremelimumab in patients with advanced solid tumors.


This is a Phase I, multicenter, open-label, dose-exploration and dose-expansion study in patients with select advanced solid tumors (NCT02261220). Eligible patients (≥18 years) will have recurrent or metastatic (R/M) disease and may have been previously treated in the R/M setting. The primary objective of this study is to assess the safety and tolerability, and maximum tolerated dose of durvalumab in combination with tremelimumab. The secondary objectives are to assess antitumor activity (including overall response rate, disease control rate, duration of response, progression-free survival, and overall survival), pharmacokinetics, pharmacodynamics, and immunogenicity of the combination. Exploratory objectives will include an assessment of biomarkers that may correlate with clinical activity of durvalumab in combination with tremelimumab. Recruitment is ongoing, with an estimated enrollment of 225–240 patients.

Trial registration identifier NCT02261220.